MyFinsight
Home
Blog
About
Contact
Download
Download image
Product sales,
net-Product
$273K
Comprehensive loss
-$26,501K
(33.48%↑ Y/Y)
Income (loss) from
discontinued operations,...
$253K
Total operating
expenses
$20K
(-99.95%↓ Y/Y)
Net loss
-$26,483K
(33.52%↑ Y/Y)
Total other
comprehensive loss
-$18K
(-200.00%↓ Y/Y)
Income (loss) from
discontinued operations, net...
$253K
(1037.04%↑ Y/Y)
General and
administrative
$20K
(-99.85%↓ Y/Y)
Loss from continuing
operations
-$26,736K
(32.84%↑ Y/Y)
Unrealized losses on
marketable securities, net...
-$18K
(-200.00%↓ Y/Y)
Loss from continuing
operations before income...
-$26,732K
(32.84%↑ Y/Y)
Income tax expense
$4K
(0.00%↑ Y/Y)
Other income, net
$3,017K
(-21.31%↓ Y/Y)
Operating loss
-$29,749K
(31.83%↑ Y/Y)
Total revenues
$570K
(13.77%↑ Y/Y)
Total operating
expenses
$30,319K
(-31.31%↓ Y/Y)
Research and development
$19,237K
(-37.84%↓ Y/Y)
General and
administrative
$11,082K
(-15.99%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)